Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Azacitidine in Newly Diagnosed AML/MDS
NCT00948064Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2009
- Primary completion
- Apr 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00948064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948064.